Prosecution Insights
Last updated: July 17, 2026
Application No. 18/222,436

METHOD AND APPARATUS FOR REDUCING EXCESS PRESSURE IN ISOCHORIC SYSTEMS

Non-Final OA §102§103
Filed
Jul 15, 2023
Priority
Jul 20, 2022 — provisional 63/390,688
Examiner
KOSAR, AARON J
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biochoric Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
552 granted / 776 resolved
+11.1% vs TC avg
Strong +30% interview lift
Without
With
+29.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
13 currently pending
Career history
794
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
47.9%
+7.9% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
13.8%
-26.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 776 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction Applicant’s election without traverse of Group I and the species (i) a liquid secondary subsystem, (ii) a positive coefficient of thermal expansion (a), (iii) a magnitude of thermal expansion that is greater than that of water, and (iv) a mass-impermeable barrier being present, in the reply filed on February 6, 2026, is acknowledged. Claims 1-31 are pending of which claims 20-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention there being no allowable generic or linking claims and claims 1-8 and 10-12 are withdrawn as being directed to non-elected species. Pending claims 9 and 13-19 have been examined on the merits. Information Disclosure Statement (IDS) The information disclosure statement (IDS) submitted on 9/23/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. An initialed copy of the IDS has been placed in the instant Application file. Please note, however, the information disclosure statements (of 9/23/2023, as marked up) fails to fully comply with 37 CFR 1.98(b)(5), which requires that each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication. MPEP 609.05(a). In the present case, examiner has considered all references filed by the applicant to expedite the prosecution. However, the applicant is informed that the references filed in an improper and/or incomplete format (lined through) should be resubmitted in a proper format to be printed in the patent. MPEP 1302.12. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 9 and 13-19 are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Powell-Palm et al (WO 2021/146122 A1; IDS). The instant claims are drawn to a process of excess-pressure-reducing in an isochoric systems comprising: (a) providing a rigid and sealable master container; (b,c) placing a biological matter-comprising primary subsystem and water-immiscible liquid secondary subsystem into the master container; wherein water has a negative coefficient of thermal expansion at sub-0 degrees C; and wherein the secondary subsystem has a positive coefficient of thermal expansion that is greater in absolute magnitude than the coefficient of thermal expansion of water; (d,e,f) removing bulk gas phase from, sealing, and cooling below-0 degrees C, the master container; (g) maintaining the master container at the desired storage temperature for a desired storage period; (h) warming the master container to a temperature that is greater than the equilibrium melting point of the primary subsystem; and (i,j) unsealing and removing the biological matter from the master container. Powell-Palm WO ‘122, however, anticipates the claims by teaching an isochoric system (constant-volume; see fig. 8 and claims 2) comprising a master container capable of receiving and retrieving therefrom a biological material and a liquid, the container being rigid, (un)sealable, configured to remove a bulk gas phase, and temperature controlled (cooled, held/maintained, and heated)(see WO ’122 at figure 8)(see instant claims 1 and the parts and functions of (a-j), claim 9, 17). The reference teaches that the system may be provided with aqueous solution ([0275]; broadly, comprising pure water, as required of claim 14). The container may be provided with additional elements, including sheaths, sleeves, etc ([014-016], broadly, mechanical elements as required of claim 15), or a plurality thereof (instant claims 17-19; [090-098]). Although WO ‘122 does not expressly recite providing a “higher than” grade 5 titanium (see instant claim 16), the reference teaches [0266] that Titanium Grade V” and “any rigid material, including metallic materials such as but not limited to Aluminum 7075, Titanium Grade 5, 316 Stainless Steel, composites such as but not limited to carbon- or glass-fiber reinforced polymers, ceramics, hard plastics, etc.” may be used and further that [0267] “may additionally be treated or coated in any manner in order to achieve a variety of improving effects”, such that the genus of materials embraced, combined with the temperature and pressure effects required of the use thereof [0268] would teach to one of skill the providing of such materials, and further the instant claims and disclosure do not limit or define what materials are intended as included or excluded thereby (and as such remain inclusive of the broad and reasonable interpretation applied herein). WO ‘122 is relied upon for the reasons discussed above. If not expressly taught therein, based upon the overall beneficial teaching provided by this reference with respect to providing an isochoric system for preserving biological materials and the benefit and conditions thereof upon reducing nucleation, and in the manner disclosed therein, the adjustments of particular conventional working conditions (e.g., determining one or more suitable material or multiplicity thereof and the ranges of conditions in which to perform such an isochoric system operation), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. From the teachings of the reference, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was effective filed, as evidenced by the references, especially in the absence of evidence to the contrary. Please note, since the Office does not have the facilities for examining and comparing Applicants’ composition with the composition of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980), and “as a practical matter, the Patent Office is not equipped to manufacture products by the myriad of processes put before it and then obtain prior art products and make physical comparisons therewith.” In re Brown, 459 F.2d 531, 535, 173 USPQ 685, 688 (CCPA 1972). Claim Objections Claim 13 is objected to because the claim depends from an objected base claim. Appropriate correction is required. Conclusion No claims are presently allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AARON J KOSAR whose telephone number is (571)270-3054. The examiner can normally be reached Mon.-Fri. 9-6 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AARON J KOSAR/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 15, 2023
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12677825
COMPOSITION FOR PROTECTING ISLET TRANSPLANTATION
3y 9m to grant Granted Jul 14, 2026
Patent 12673081
TRADITIONAL CHINESE MEDICINE COMPOUND COMPOSITION WITH IMMUNE BIDIRECTIONAL REGULATION EFFECT AND PREPARATION METHOD AND APPLICATIONS THEREOF
4y 7m to grant Granted Jul 07, 2026
Patent 12648982
HERBAL MEDICINE COMPOSITION AND METHODS OF USING SAME
1y 1m to grant Granted Jun 09, 2026
Patent 12644806
METHOD AND DEVICE FOR ULTRA-RAPID CRYO-FIXATION OF A SAMPLE FOR MICROSCOPIC STUDIES
2y 7m to grant Granted Jun 02, 2026
Patent 12635683
PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES AND METHODS OF STORING AND TRANSPORT
3y 6m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+29.9%)
3y 5m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 776 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month